HPP593 is a functionally selective peroxisome proliferator-activated receptor delta (“PPAR-delta”) agonist that does not exhibit off-target activity. In December 2017, we licensed worldwide rights to develop and commercialize HPP593 to Reneo Pharmaceuticals.
PPAR-delta, a member of the nuclear regulatory superfamily of ligand-activating transcriptional regulators, is expressed in most metabolically active tissues throughout the body. Studies in mice have shown that PPAR-delta agonists induce genes related to mitochondrial biogenesis. PPAR-delta activation by agonists also reduces blood glucose, improves insulin insensitivity and regulates inflammation.
HPP593 has completed three phase 1 studies of up to 28 days in duration. HPP593 was well tolerated at all doses tested.